Monte Rosa Therapeutics (GLUE) insider trading in the last 6 months
3 insiders sold $451K. No buys.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Form 4 filings, newest first
Who files at Monte Rosa Therapeutics
Questions about GLUE's insider trades
Are GLUE insiders buying or selling?
3 insiders sold $451K across 3 filings in the last 6 months. No open-market buys on record. The newest filing: Matthew Bowen, Principal Accounting Officer, sold $137.28 on Oct 5, 2026.
Who are GLUE's biggest insider sellers?
By the dollars of their sales in the last 6 months: Anthony M. Manning (Director), 1 sale; Markus Warmuth (President & CEO), 1 sale; Matthew Bowen (Principal Accounting Officer), 1 sale.
When did a GLUE insider last buy?
No GLUE insider bought shares on the open market in the last 6 months, as filed on Form 4. The newest filing is a sale by Matthew Bowen on Oct 5, 2026.
Monte Rosa Therapeutics's page has its Quality Score, its chart, and its earnings. More in Healthcare and Biotech.